2020年雷帕鸣在国内上市了吗？

Rapamune (sirolimus) is a lipophilic nitrogen-containing 36$ macrolide antibiotic naturally produced from Streptomyees hygroscopicus. Rapamune is suitable for patients who have received kidney transplants to prevent organ rejection.

Sirolimus (sirolimus) has been marketed in China and was approved for domestic marketing in 2003.

Rapamin (sirolimus) inhibits the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukin-2, IL-4? and IL-15) through a completely different mechanism from other immunosuppressants. Rapamin also inhibits the production of antibodies. In cells, rapamycin binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate an immunosuppressive complex.

Clinical trials explore the clinical efficacy and safety of sirolimus (sirolimus) in kidney transplantation. Methods A total of 23 patients with kidney transplantation were treated with triple immunosuppressive therapy of this product combined with cyclosporine and glucocorticoids. Start taking this product within 48 hours after transplantation, with a loading dose of 6 mg and a maintenance dose of 2 mg. The results showed that 22 patients completed 6 to 12 months of follow-up. The incidence rates of acute rejection (AR) at 6 and 12 months were 13.6% (3 cases/22 cases) and 15.8% (3 cases/19 cases) respectively. AR patients were reversed after methylprednisolone pulse treatment and continued to be followed up for more than half a year. No recurrence of AR was found. The main adverse reaction was hyperlipidemia (56.5%, 13 cases/23 cases). After reducing the dosage of sirolimus or applying lipid-lowering drugs, the patient's blood lipids dropped to normal or slightly higher than normal levels. Graft vascular disease and cardiovascular complications have not increased since follow-up.